Acadia Healthcare Company, Inc. (ACHC) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Acadia Healthcare is a leading publicly traded pure-play provider of behavioral healthcare services in the U.S., operating 258 facilities with approximately 11,400 beds across 38 states and Puerto Rico. The company provides acute inpatient psychiatric care, specialty treatment, comprehensive treatment centers (CTCs), and residential treatment.
Key Financial Metrics (Six Months Ended June 30, 2024)
| Metric | 2024 (YTD) | 2023 (YTD) | Change |
|---|---|---|---|
| Revenue | $1,564.1 million | $1,435.6 million | +9.0% |
| Net Income (Attributable to ACHC) | $154.9 million | $138.3 million | +12.0% |
| Diluted EPS | $1.68 | $1.51 | +11.3% |
| Operating Cash Flow | ($150.1 million) used | $208.2 million provided | Significant Decrease |
| Total Debt (Long-term + Current) | $1,841.1 million | $1,371.8 million | +34.2% |
| Cash and Equivalents | $77.2 million | $100.1 million | -22.9% |
Revenue Mix (YTD 2024): Medicaid (56.9%), Commercial (25.9%), Medicare (14.1%), Self-Pay (1.9%).
Material Changes vs. Prior Period
- Revenue Growth: Driven by an 8.8% increase in same-facility revenue, resulting from a 6.2% increase in revenue per patient day and a 2.4% increase in patient days. Acute inpatient psychiatric facilities contributed the largest revenue share ($829.8 million YTD).
- Expense Increases: Salaries, wages, and benefits rose to $837.3 million (53.5% of revenue) due to wage inflation and equity-based compensation ($17.5 million). Interest expense increased to $56.4 million (from $40.9 million) due to new borrowings.
- Impairment Charges: Loss on impairment decreased significantly to $1.0 million (YTD 2024) compared to $8.7 million (YTD 2023), reflecting fewer facility closures.
- Capital Expenditures: Investing cash outflows surged to $340.1 million, primarily due to $296.7 million in capital expenditures (mostly expansion) and $50.7 million for acquisitions.
- Debt Financing: The company incurred $350.0 million in Incremental Term Loans and borrowed $160.0 million on its revolving credit facility to fund growth and the Desert Hills settlement.
Guidance, Outlook, and Risks
- Expansion Outlook: Management expects to add approximately 1,200 total beds and open up to 14 CTCs by year-end 2024, excluding acquisitions.
- Desert Hills Litigation: The company paid a $400.0 million settlement in January 2024 to resolve the "Desert Hills Litigation" (Inman, Rael, and Endicott-Quinones cases). A sixth lawsuit (CNRAG) was filed in February 2024; the company states it cannot quantify the ultimate liability at this time.
- Government Investigation: A tentative agreement to resolve a government investigation regarding regulatory compliance at certain facilities is recorded as a $19.9 million liability.
- Liquidity: Operating cash flow turned negative ($150.1 million used) due to significant working capital changes and the timing of the settlement payment, offset by substantial financing inflows. The company maintains $371.5 million in availability under its revolving credit facility.
- Risk Factors: Key risks include labor shortages, inflation, regulatory compliance, and the impact of Medicaid eligibility changes post-pandemic.
Investor Verification Checklist
- Settlement Impact: Verify the full financial impact of the $400 million Desert Hills settlement payment on liquidity and future cash flows.
- Working Capital Trends: Analyze the significant increase in accounts receivable and the negative operating cash flow to ensure collection trends remain stable.
- Debt Covenants: Confirm continued compliance with the Credit Facility's leverage ratio (max 4.5:1) and interest coverage ratio (min 3.0:1) given the increased debt load.
- Capital Expenditure ROI: Assess the timeline for revenue generation from the $252.5 million in expansion capital expenditures.
- Pending Litigation: Monitor developments in the sixth Desert Hills lawsuit (CNRAG) for potential additional liabilities.